|
|
Vaccine Detail
|
Adenovirus-PSA Prostate Cancer Vaccine |
| Vaccine Information |
- Vaccine Name: Adenovirus-PSA Prostate Cancer Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007210
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: PSA
- Prostate specific antigen
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The vaccine uses an adenovirus that carries the gene for prostate specific antigen in conjunction with the use of a collagen matrix (Lubaroff et al., 2009).
- Description: A cancer vaccine composed of a genetically engineered, replication-deficient type 5 adenovirus carrying the human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with the adenovirus-PSA prostate cancer vaccine, the adenovirus infects cells and expresses PSA. In turn, PSA may activate the immune system and may induce a cytotoxic T-lymphocyte response against PSA-expressing tumor cells. PSA, a tumor associated antigen, is expressed by prostate epithelial cells and is overexpressed in prostate cancer. (NCIT_C102541).
|
| Host Response |
|
|
| References |
Lubaroff et al., 2009: Lubaroff DM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M, Howard J, Paisley J, Boeglin D, Ratliff TL, Williams RD. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(23); 7375-7380. [PubMed: 19920098].
NCIT_C102541: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102541]
|
|
